Label-to-MedDRA Mapping for Unlabeled Signal Prioritization
Maps label language to MedDRA terms to speed identification of potentially unlabeled case signals Evidence basis: FDA-associated evaluations showed NLP can map adverse-event terms in labels to MedDRA with practical precision and recall; shared-task results indicate strong triage support but not full replacement of expert safety review
The Problem
“Map product label language to MedDRA terms to prioritize potentially unlabeled safety signals faster”
Organizations face these key challenges:
Label wording often differs from MedDRA preferred terms and lower-level terms
Manual mapping is slow and dependent on scarce safety experts
Keyword search misses synonyms, context, and hierarchical MedDRA relationships
Global safety teams struggle to unify evidence from labels, ICSRs, literature, EHR, and RWD sources
Triage support is useful, but expert review is still required for regulatory-grade decisions
Auditability and traceability are mandatory for pharmacovigilance workflows
Impact When Solved
The Shift
Human Does
- •Review product label language for adverse event terms
- •Manually map label terms to MedDRA concepts
- •Compare mapped terms against case signals to find potential gaps
- •Coordinate findings in spreadsheets and tracking documents
Automation
- •No AI-driven mapping support in the legacy workflow
- •No automated prioritization of potentially unlabeled signals
- •No continuous monitoring of mapping consistency
- •No system-generated triage recommendations
Human Does
- •Approve mapping rules and prioritization criteria
- •Review AI-flagged unlabeled signal candidates for clinical relevance
- •Resolve ambiguous or low-confidence term mappings
AI Handles
- •Extract adverse event language from product labels
- •Map label terms to MedDRA concepts and normalize variants
- •Prioritize potential unlabeled case signals based on mapping results
- •Flag low-confidence mappings and exceptions for human review
Operating Intelligence
How Label-to-MedDRA Mapping for Unlabeled Signal Prioritization runs once it is live
AI runs the first three steps autonomously.
Humans own every decision.
The system gets smarter each cycle.
Who is in control at each step
Each column marks the operating owner for that step. AI-led actions sit above the divider, human decisions and feedback loops sit below it.
Step 1
Assemble Context
Step 2
Analyze
Step 3
Recommend
Step 4
Human Decision
Step 5
Execute
Step 6
Feedback
AI lead
Autonomous execution
Human lead
Approval, override, feedback
AI handles assembly, analysis, and execution. The human gate sits at the decision point. Every cycle refines future recommendations.
The Loop
6 steps
Assemble Context
Combine the relevant records, signals, and constraints.
Analyze
Evaluate options, risk, and likely outcomes.
Recommend
Present a ranked recommendation with supporting rationale.
Human Decision
A human accepts, edits, or rejects the recommendation.
Authority gates · 1
The system must not determine that a signal is unlabeled, partially labeled, or requires escalation without review by qualified safety staff. [S2][S3]
Why this step is human
The decision carries real-world consequences that require professional judgment and accountability.
Execute
Carry out the approved action in the operating workflow.
Feedback
Outcome data improves future recommendations.
1 operating angles mapped
Operational Depth
Technologies
Technologies commonly used in Label-to-MedDRA Mapping for Unlabeled Signal Prioritization implementations:
Key Players
Companies actively working on Label-to-MedDRA Mapping for Unlabeled Signal Prioritization solutions:
Real-World Use Cases
Regulatory labeling update recommendation from post-market safety signals
When enough evidence builds that a medicine may harm patients in a new way, the FDA can update the drug label to warn doctors and patients.
Cloud-based safety analytics using RWD/RWE and EHR-connected data
The platform pulls together safety information from real-world sources like health records so teams can see drug safety trends faster.